ReviewNatural product reports2015
Biological targets and mechanisms of action of natural products from marine cyanobacteria.
Review in Natural product reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Pooled it
- Harnessing engineered cyanobacteria for next-generation therapeutics.Archives of microbiology · 2026Review
- Evaluation of physcion isolated from endophytic Aspergillus fumigatus ASH3 as an antiviral agent against coxsackievirus B4 and herpes simplex virus type 1: in silico-supported in vitro study.Folia microbiologica · 2026Article
- Reviewing Marine Bioactive Compounds From the Red Sea: Advancing Therapeutic Applications While Navigating Translational and Conservation Challenges.Chemistry & biodiversity · 2026Review
- Structure Determination and Biosynthesis of Dapalides A-C, Glycosylated Kahalalide F Analogues from the Marine CyanobacteriumJournal of natural products · 2025Article
- Anticancer Activity of Secondary Metabolites Extracted from Endophytic Fungus in Pongamia pinnata Barks.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Peptide surfactants with post-translational C-methylations that promote bacterial development.Nature chemical biology · 2025Article
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Optimizing Encapsulation of Active Compounds of Carrot By-Product in TPP-Chitosomes.Foods (Basel, Switzerland) · 2024Article
- Plant-based compositions for the treatment of local and topical bacterial infections: a patent review.Future microbiology · 2024Review
- More than just an eagle killer: The freshwater cyanobacteriumProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Identification, Heterologous Expression, and Characterization of the Tolypodiol Biosynthetic Gene Cluster through an Integrated Approach.ACS chemical biology · 2023Article
- Review of Marine Cyanobacteria and the Aspects Related to Their Roles: Chemical, Biological Properties, Nitrogen Fixation and Climate Change.Marine drugs · 2023Review
- Isolation and Biological Activity of Iezoside and Iezoside B, SERCA Inhibitors from Floridian Marine Cyanobacteria.Marine drugs · 2023Article
- New Nostocyclophanes fromMarine drugs · 2023Article
- Metabolomics Applied to Cyanobacterial Toxins and Natural Products.Advances in experimental medicine and biology · 2023Review
- Naturally Occurring Organohalogen Compounds-A Comprehensive Review.Progress in the chemistry of organic natural products · 2023Review
- Mechanism of Action of Ribosomally Synthesized and Post-Translationally Modified Peptides.Chemical reviews · 2022Review
- Marine Cyanobacteria as Sources of Lead Anticancer Compounds: A Review of Families of Metabolites with Cytotoxic, Antiproliferative, and Antineoplastic Effects.Molecules (Basel, Switzerland) · 2022Review
- Genome Mining as an Alternative Way for Screening the Marine Organisms for Their Potential to Produce UV-Absorbing Mycosporine-like Amino Acid.Marine drugs · 2022Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Marine cyanobacteria are an ancient group of organisms and prolific producers of bioactive secondary metabolites. These compounds are presumably optimized by evolution over billions of years to exert high affinity for their intended biological target in the ecologically relevant organism but likely also possess activity in different biological contexts such as human cells. Screening of marine cyanobacterial extracts for bioactive natural products has largely focused on cancer cell viability; however, diversification of the screening platform led to the characterization of many new bioactive compounds. Targets of compounds have oftentimes been elusive if the compounds were discovered through phenotypic assays. Over the past few years, technology has advanced to determine mechanism of action (MOA) and targets through reverse chemical genetic and proteomic approaches, which has been applied to certain cyanobacterial compounds and will be discussed in this review. Some cyanobacterial molecules are the most-potent-in-class inhibitors and therefore may become valuable tools for chemical biology to probe protein function but also be templates for novel drugs, assuming in vitro potency translates into cellular and in vivo activity. Our review will focus on compounds for which the direct targets have been deciphered or which were found to target a novel pathway, and link them to disease states where target modulation may be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.